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Abstract: Anemia is common in cancer, and lymphoproliferative disease is no exception. 
Erythropoiesis-stimulating agents (ESA) have been used for renal anemia since 1986, and 
considerably later in cancer anemia. The ﬁ  rst studies were published around 1993, but the use 
of ESA did not become common in cancer anemia until in the late 1990s. Cancer anemia is still 
under-treated. This review gives an overview of the use of ESA in hematologic malignancies. 
A background is given about this treatment in the cancer ﬁ  eld generally. The pathophysiology 
of cancer anemia is described with special emphasis on the disturbances in iron metabolism. 
Functional iron deﬁ  ciency has been shown to be both frequent and important as a hindrance 
for response to ESA treatment, and recent studies are reported in some detail, where the use of 
intravenous iron was shown to improve the response rate of ESA treatment.
Keywords: Epo, epoetin, ESA, cancer anemia, lymphoma, myeloma, lymphoproliferative 
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Background
Cancer patients may be anemic for a variety of reasons. It is good clinical practice 
always to bear in mind that other etiologies than the cancer itself may be at hand, even 
though the most common causes of anemia in general, like iron deﬁ  ciency, are not 
very prevalent in hematological malignancies. However, exclusion of deﬁ  ciency of 
iron, folate, and B12, as well as immunologically induced hemolytic anemia, should 
be part of the work-up of anemia even in this situation.
In general, anemia is common in lymphoproliferative disorders (lymphoma and 
multiple myeloma). Kyle (1975) reported Hb   12 g/dl in 73% of newly diagnosed 
myeloma patients and Moullet and colleagues (1998) found Hb   11 g/dl in 32% 
of newly diagnosed non-Hodgkin´s lymphoma patients. In a more recent study, the 
European Cancer Anaemia Survey (ECAS) (Ludwig et al 2004; Birgegård et al 2006) 
enrolled 2360 lymphoma and myeloma patients: 52.5% were anemic at enrolment 
and 73% showed a Hb   12 g/dl during a 6-month follow-up period (Figure 1). As 
explained below, erythropoiesis is inhibited by complex mechanisms connected to 
the cancer itself. However, a close connection to cytostatic treatment has also been 
established. During CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) 
treatment 79% of the patients developed mild to moderate anemia and 49% World 
Health Organization (WHO) grade 3–4 anemia in a study by Groopman and Itri (1999). 
In the ECAS study, chemotherapy was the strongest factor contributing to anemia. 
In another multi-centre study it was found that the prevalence of anemia with Hb levels 
between 8 and 10.5 g/dl increased progressively with the number of chemotherapy 
cycles in patients with lymphoma (Coifﬁ  er et al 2001).
When recombinant human erythropoietin (rHuEpo) became available around 
1986, its use was  ﬁ  rst limited to patients with renal anemia. There were pilot studies 
in cancer from 1993 onwards, but it was not until about 10 years after rHuEpo had Therapeutics and Clinical Risk Management 2008:4(2) 528
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become an established treatment form in renal anemia that 
larger studies in cancer anemia were undertaken. In recent 
years, the importance of the Hb level for physical capacity 
and quality of life (QoL) has been extensively investigated, 
and as a result the use of erythropoiesis-stimulating agents 
(ESA) in cancer patients has increased.
Pathophysiology of cancer anemia
Normal erythropoiesis is a dynamic and complex process 
that maintains the Hb level within a relatively narrow range 
under changing physiologic conditions (Mercadente et al 
2000; Birgegård et al 2005). The homeostatic balance is 
upheld via a sensitive system where hypoxia induces tran-
scription of erythropoietin (Epo), produced by the kidneys. 
The Epo response depends on the hypoxia signal, not on the 
absolute number of erythrocytes in the blood, and therefore 
compensating mechanisms may modify the Epo expression. 
The cardiovascular and respiratory response, the increase 
in 2,3BPG in the red cells, leading to a right-shift of the 
oxygen dissociation curve, increasing oxygen unloading, 
and lowering of the pH in the capillaries of vital organs, 
also enhancing oxygen delivery, all seek to compensate for 
a lowering of the oxygen carrying capacity. The efﬁ  cacy of 
these compensatory mechanisms may vary between indi-
viduals, and this explains the variability in the expression 
of symptoms as well as the subjective experience of anemia 
in individual patients.
The anemia of cancer patients is a form of the anemia of 
chronic disease (ACD), which is a multifactorial condition, 
to a large extent caused by production of cytokines with a 
detrimental effect on the production of red cells (Figure 2). 
These cytokines are both inﬂ  ammatory and paramalignant, 
and they exert their effect both on the level of Epo production 
(Miller et al 1990; Faquin et al 1992) and the proliferation and 
differentiation in the erythroblast compartment of the bone 
marrow (Mercadente et al 2000; Nowrousian 2002). Further-
more, there are important effects on the iron metabolism.
Inﬂ  ammatory cytokines induce the expression of the most 
important iron distribution regulator hepcidin, which in turn 
down-regulates and increases degradation of ferroportin, the 
sole exporter of iron from within the cells to the plasma com-
partment (Roy and Andrews 2005; Nemeth and Ganz 2006). 
This leads to a decreased transport of iron across the gut brush 
border as well as from the macrophages to the plasma. Most 
of the iron released to plasma from macrophages comes from 
the break-down of senescent red cells. When this release of 
macrophage iron is decreased, plasma transferrin saturation 
is lowered, and the erythroblasts in the bone marrow are 
starved for iron. Simultaneously, iron is accumulated in the 
macrophages, explaining why these patients have a normal 
Figure 1 Frequency of anemia in 2165 lymphoma and myeloma patients during a 6 month follow-up period in the ECAS study. Copyright © 2006. Reproduced with permission 
from Birgegård G, Gascón P, Ludwig H. 2006. Evaluation of anemia in patients with multiple myeloma and lymphoma: ﬁ  ndings of the European Cancer Anemia Survey. Eur J 
Haematol, 77:378–86.Therapeutics and Clinical Risk Management 2008:4(2) 529
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or even elevated s-ferritin level. The normal turnover of iron 
from the macrophages to the bone marrow erythroblasts 
comprises about 30 mg of iron or 15–20 times the daily 
absorption, indicating how important this reutilisation of 
iron is in comparison with the daily uptake.
This hepcidin-induced disturbance of iron turnover has 
been named functional iron deﬁ  ciency (FID) and seems to be 
a major problem in cancer anemia (Cavill et al 2006; Hedenus 
et al 2007). The problems with iron support of erythropoiesis 
in ACD become even more prominent during treatment with 
ESA, since it effectively hinders a response in many patients. 
Furthermore, if ESA treatment successfully stimulates red 
cell proliferation, more iron is needed. A doubling of the 
reticulocyte count is often achieved, and this also means a 
doubling of the iron need, or about 60 mg of iron per day 
transported through plasma. Under other conditions, like in 
B12 deﬁ  ciency anemia treatment, this is no problem, but in 
ACD the hepcidin–ferroportin interaction reduces the pos-
sibility for iron provision to the bone marrow.
Other contributing factors to the anemia of chronic dis-
ease are shortened red cell life span, nutritional deﬁ  ciencies, 
and renal dysfunction.
Anemia treatment in cancer
As shown above, anemia is a common problem in cancer. 
The seriousness of the problem is a matter of controversy. 
Traditionally, a mild anemia has not been considered a con-
dition worth treating, and even recently, the ECAS study 
showed that less than 50% of anemic patients had any anemia 
treatment (Ludwig et al 2004). One of the reasons for this 
controversy is probably that the tolerance for anemia is so 
variable; some patients have no symptoms and no decline 
in functional capacity even in moderate anemia. From this 
it has been tempting to conclude that symptoms in anemic 
patients are not due to the anemia itself.
However, a large number of studies, not least in nephrol-
ogy patients, have shown that correcting anemia has led to 
improvements in physical capacity, cognitive function, and 
QoL. Meta-analysis of treatment studies in mixed cancer 
populations have shown not only that ESA treatment reduces 
transfusions and increases Hb levels (Seidenfeld et al 2001), 
but also has a positive effect on QoL (Glaspy et al 1997; 
Demetri et al 1998; Crawford et al 2002; Gabrilove et al 
2001; Littlewood et al 2001; Quirt et al 2001; Cella 2002; 
Fallowﬁ  eld et al 2002; Cella et al 2003a; Vansteenkiste and 
Figure 2 Pathophysiology of cancer anemia.
Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.Therapeutics and Clinical Risk Management 2008:4(2) 530
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Wauters 2005; Witzig et al 2005). This was also related to 
fatigue studies in the general population, showing that the 
fatigue of cancer patients was far from “normal” (Cella et al 
2003b). I nterestingly, a direct correlation between the mag-
nitude of the Hb increase and the improvement of QoL was 
shown by Crawford and colleagues (2002). In an analysis 
of the studies by Glaspy, Demetri, and Gabrilove (a total of 
more than 6000 patients) an incremental analysis showed a 
correlation between Hb level and QoL score over the range 
of 8–14 g/dl, and the greatest improvement in QoL scores, 
for every 1 g/dl Hb increase, was seen in the range of 11 to 
12 g/dl (Crawford et al 2002).
Fatigue in cancer patients is multifactorial, and needs to 
be addressed with a wider perspective than just that of ane-
mia. However, an important role for anemia in the fatigue 
of cancer patients has been found (Cella 2002).
These results have changed the attitudes to mild to moder-
ate anemia, and recent guidelines for ESA treatment indicate 
a role for ESA in cancer anemia even in mild to moderate 
anemia (see below).
A further analysis of ESA treatment in solid tumor 
patients is outside the scope of this review. Recently, two 
studies have raised concerns that rHuEpo may adversely 
affect the survival and tumor progression of cancer patients 
(Henke et al 2003; Leyland-Jones et al 2005). In those tri-
als, decreased survival and increased tumor progression 
were found in patients who received rHuEpo compared 
with patients who received placebo. Both studies have been 
criticized. Both used a Hb treatment goal above the recom-
mended. In the breast cancer study, which included patients 
with very advanced disease, the death rate was high, and the 
difference was shown within the ﬁ  rst three months, making 
it less likely that the rHuEpo treatment was the reason for 
the difference. In the head- and neck cancer study, there 
was an imbalance between the treatment arms with regard 
to smoking and the tumour status after operation, and in 
the patients actually treated according to protocol there 
was no signiﬁ  cant difference. Nevertheless, caution has 
been recommended, especially during radiotherapy of solid 
tumours, and a number of hypotheses have been proposed to 
explain the potential role of ESAs, among them Epo receptor 
(EpoR) tumor stimulation, tumor neovascularization, and 
enhanced tumor oxygenation. A fundamental problem in 
the research on EpoRs is that the antibodies generally used 
are polyclonal, and detect other proteins as well. Therefore, 
it has been shown that anti-Epo receptor antibodies do not 
predict EpoR expression. EpoRs have been found in a variety 
of normal tissues at considerably lower expression levels 
than in bone marrow, and the levels found on tumors do not 
differ from normal tissue (Elliott et al 2006). In the in vitro 
tumor cell stimulation studies, suprapharmacological doses 
of rHuEpo have been used. So far, when this review is writ-
ten, no in vivo animal tumor study has shown that treatment 
with ESAs alone enhances tumor progression or reduces 
survival. It is unfortunate that survival was not an end-point 
in the many previous ESA studies, but hopefully ongoing, 
well-controlled clinical trials will clarify the safety issue of 
ESA use in cancer.
Anemia treatment in lymphoproliferative 
disease
The anemia problem in lymphoma and multiple myeloma 
is greater than in many other cancer forms (Birgegård et al 
2006). As cited above, the ECAS study showed that 73% of 
lymphoma and myeloma patients had a Hb   12g/dl at any 
time during a 6 month follow-up period, and during CHOP 
treatment 79% of the patients developed mild to moderate 
anemia and 49% WHO grade 3–4 anemia in a study by 
Groopman and Itri (1999).
In the ECAS study, a signiﬁ  cant correlation was found 
(p   0.001) between WHO performance score and mean 
Hb at enrolment (Ludwig et al 2004). The lymphoma and 
myeloma population is generally old and comorbidity is 
common, also compromising the functional capacity and 
mental reserves of the patients.
Efﬁ  cacy of ESA treatment in lymphoma
and myeloma patients
Myeloma and lymphoma patients were included in a large 
number of ESA treatment studies with mixed cancer popula-
tions, both nonrandomized and randomized. Lately, a number 
of randomized, controlled studies have also been performed in 
myeloma and lymphoma patients. Response to ESA therapy 
has generally been deﬁ  ned as an increase in Hb of  2 g/dl, 
and response rates vary between investigations, depending on 
the proﬁ  le of the study populations. A typical ESA study in 
myeloma and lymphoma patients would have a response rate 
of 50%–70%. Lower ﬁ  gures would be expected in trials with 
many patients with advanced disease and very low baseline Hb, 
and better responses in patients with a higher baseline Hb. This 
is supported by data from a randomized, placebo-controlled 
study, where response was seen in 68.5% of patients with a 
baseline Hb   10.5 g/dl compared with 80.5% in the patients 
with baseline Hb   10.5 g/dl (Dammacco et al 2001).
The efﬁ  cacy of ESA treatment in increasing Hb levels 
was shown in a randomized, placebo-controlled study in Therapeutics and Clinical Risk Management 2008:4(2) 531
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nonmyeloid malignancies, where the responses rates were 67% 
vs 27% in the epoetin beta and placebo groups, respectively 
(p   0.0001) (Osterborg et al 2002). Three large open-label, 
nonrandomized, community-based studies with more than 
2000 patients each (Glaspy et al 1997; Gabrilove et al 2001), 
all showed a Hb increase of 1.8–2.0 g/dl from base-line, and 
this magnitude of the Hb increase has been common in later, 
randomized studies as well (Dammacco et al 2001; Hedenus 
et al 2003). The treatment time has generally been 12–16 
weeks, enough to catch even late responders but of course too 
short for evaluation of impact on survival. There is almost no 
information about long-term ESA treatment in myeloma and 
lymphoma in randomized studies. The reasons for this are 
many: there are ethical considerations against keeping patients 
in a long-term control arm anemic, and there is difﬁ  culty in 
collecting large patient groups of long-term survivors who 
still are anemic. However, there is a large experience among 
clinicians of patients with long-term responses in palliative 
treatment of myeloma and lymphoma.
Due to the cost of ESA treatment, there has been reluc-
tance among clinicians to prescribe these drugs, especially 
in situations where the anemia can be expected not to last for 
a long time. If the patient is not anemic at the start of tumor 
therapy, anemia may ensue a month or more into a 3-month 
long period of chemotherapy like CHOP-14 × VI, and since 
response to ESA treatment is mostly seen only after about 
4–6 weeks, the time that the patient beneﬁ  ts may be too 
short to warrant the cost. It may be argued that the anemia 
is often more long-lasting than the treatment and that early 
intervention may make anemia avoidable.
Effectiveness of ESA treatment in lymphoma
and myeloma
It is a matter of controversy whether an increase in Hb levels 
is a goal in itself in these patients. Anemia affects virtually 
all organs systems in the body (Ludwig and Strasser 2001), 
and it stands to reason that cancer patients would beneﬁ  t from 
correcting anemia. However, ESA are expensive drugs, and 
doctors as well as funding authorities have expectations of 
objectively proven gains in order to support treatment.
Originally, the focus was on the avoidance of red cell 
transfusions, and in all studies it was seen that ESA treat-
ment could reduce the number of transfusions. However, the 
effectiveness was questioned on the grounds that as many as 
four ESA-treated patients were needed to make one patient 
transfusion-independent (Seidenfeld et al 2002).
The strong correlation between prognosis and Hb levels at 
diagnosis makes it tempting to hypothesise that treatment of 
anemia would improve survival. In a small study in chronic 
lymphocytic leukemia (CLL) patients (n = 33), maintenance 
therapy with rHuEpo showed a direct and strong correla-
tion to a sustained response to tumor therapy: all patients 
on rHuEpo maintenance remained responsive, whereas all 
patients without rHuEpo maintenance relapsed (Siakantaris 
et al 2000). The same group of investigators later showed 
that 15/20 CLL patients could be down-staged in the Rai 
staging from stage III after response to Epo therapy. Chemo-
therapy was avoided or postponed in responders (Pangalis 
et al 2002). Unexplained myeloma regression in patients and 
antimyeloma effects in murine systems have been shown by 
one group (Mittelman et al 1997, 2001, 2004). However, in 
spite of these reports, meta-analyses fail to show an improved 
survival or tumor control in ESA-treated patients in random-
ized studies (Bohlius et al 2006a), and no larger single study 
has shown a signiﬁ  cant survival advantage. Unlike in solid 
tumors, there is no indication of a negative effect in myeloma 
or lymphoma.
Since survival beneﬁ  t has not been proven, other objec-
tive beneﬁ  ts must be shown to justify treatment. Therefore, 
the most obvious effect of increasing Hb levels from a 
clinical perspective, the improvement of QoL, has come 
into focus.
Quality of life studies
QoL has been studied in a large number of ESA treatment 
studies in cancer and the results have constantly been posi-
tive for ESA treatment. This is true for solid tumors as well 
as myeloma and lymphoma and for patients with or without 
chemotherapy. The most widely used QoL measurement 
is the Functional Assessment of Cancer Therapy (FACT) 
instrument with its anemia subscale FACT-An, published 
and validated by Cella and others (Cella 1997; Yellen et al 
1997). A prospective, randomized, placebo-controlled study 
with over 300 myeloma and lymphoma patients showed 
major improvements in FACT-An as well as Linear Analogue 
Scales (LASA) for the patients who had a Hb improvement 
from ESA treatment (Littlewood et al 2001), and this univari-
ate analysis was later supported by a multiple linear regression 
analysis of the same material, accounting for disease progres-
sion and other possible confounding factors (Fallowﬁ  eld et al 
2002). Hedenus and colleagues (2003) found a statistically 
signiﬁ  cant relationship (p   0.001) between change in Hb 
and change in FACT-An scores and also showed that patients 
with a lower base-line FACT-An score reported the largest 
improvements. A correlation between the magnitude of the 
Hb change and the QoL gain was earlier found in the large Therapeutics and Clinical Risk Management 2008:4(2) 532
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nonrandomized study by Gabrilove and colleagues (2001) 
(Figure 3). Dammacco and colleagues (2001) showed, apart 
from an improvement in QoL in the ESA treatment arm, 
also a signiﬁ  cantly better performance score in the treated 
patients. In a study of 349 myeloma and lymphoma patients, 
Österborg and colleagues (2002) conﬁ  rmed a QoL gain in the 
ESA-treated patients and a correlation between Hb increase 
and QoL improvement.
From all these studies, and others, it may be concluded 
that improvement in QoL is strongly correlated to Hb 
increase, a correlation that gives strong support for the notion 
that anemia is an important factor in the symptoms and the 
well-being of cancer patients.
Unfortunately, there is a lack of data concerning objec-
tive measures of effects on physical performance, cognitive 
functions, cardiovascular effects, etc., in the literature on 
treatment of cancer anemia. This is in contrast to the area of 
renal anemia, where such studies have given support to the 
importance of correction of anemia.
Indications for ESA treatment
Before initiating ESA therapy, the clinician would like to 
have reliable indicators of the chance for a positive treatment 
response. Attempts have been made to identify patients with a 
small chance for response in order to avoid fruitless treatment 
attempts. The baseline s-Epo level has been identiﬁ  ed as a 
predictor on the group level (Henry et al 1995; Cazzola et al 
1996; Macdougall et al 1996; Macdougall 1998). This has 
been challenged in recent studies, especially in myeloma 
and lymphoma patients (Katodritou et al 2004). Also, in 
the individual patient a cut-off level identiﬁ  ed as an optimal 
predictor for the group has little value. With a s-Epo above 
100 U/L, which has often been found to be a group response 
predictor, still a considerable percentage of cancer patients 
respond to ESA therapy.  Furthermore, cancer patients have 
a blunted Epo response to anemia (Miller et al 1990), a vast 
majority of them showing s-Epo levels below 200 u/L (Henry 
et al 1995). Therefore, s-Epo measurement before treatment 
start has limited value.
Several guidelines for ESA treatment have been pub-
lished (Bokemeyer et al 2004; Djulbegovic 2005). Since 
new studies tend to change the recommendations, the value 
of guidelines is closely connected to the year of publica-
tion. The most recent are the updated EORTC guidelines, 
published last year (Bokemeyer et al 2007). Forty-three 
new publications and 78 relevant abstracts were added 
since the last update 3 years earlier. In the new EORTC 
guidelines, which states the evidence grade for each rec-
ommendation, initiation of therapy is recommended at a 
Hb level of 9–11 g/dl, based on anemia-related symptoms. 
Figure 3 The relationship between increase in Hb and change in LASA QoL scores. The more Hb levels increased, the greater was the improvement in QoL scores. Copyright 
© 2001. Reprinted with permission from the American Society of Clinical Oncology. Gabrilove JL, Cleeland CS, Livingston RB, et al 2001. Clinical evaluation of once-weekly 
dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol, 19:2875–82.Therapeutics and Clinical Risk Management 2008:4(2) 533
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Table 1 Condensed EORTC 2007 guidelines for erythropoiesis-
stimulating agents treatment
Hb initiation level  9–11 g/dl
Early intervention,   Yes, with falling Hb and further
Hb   12 chemotherapy  planned
Prophylactic treatment  No
Additional oral iron  No
Additional Iv iron  Yes
Elderly patients  Treatment as younger
Dose escalation  No
Dosing  Epo alfa and beta QW, darbepoetin
  QW or Q 3W
Target Hb level  12–13 g/dl
Goal of therapy  QoL improvement and transfusion
 prevention
Higher starting dose  No
Abbreviation: QoL, quality of life.
However, treatment may be started even at a Hb   12 g/dl 
to prevent further decline in Hb in patients with falling Hb 
levels and a planned further cytostatic treatment with a high 
risk of worsening anemia. The target Hb level is given as 
12–13 g/dl, and the two major goals of treatment should 
be improvement of QoL and avoidance of red blood cell 
transfusions (Table 1).
In this context it should be pointed out that a reduction 
of previous levels of physical and social function should be 
deﬁ  ned as a symptom. Patients with anemia tend to reduce 
their activities in order to avoid open symptoms of anemia 
and this reduction of capacity may easily go unnoticed.
A recent study by Straus and colleagues (2006) is of 
special interest with regard to the initiation of ESA therapy. 
Almost 300 patients with lymphproliferative disease were 
randomized to early (Hb   12 g/dl) or late ( 9 g/dl) treat-
ment start. All had a transferrin saturation  20% and 
s-ferritin  50 ug/L. The treatment goal was Hb 13–15 g/dl. 
The Hb level increased in the “early” treatment group and 
decreased in the “late” group (p   0.0001). More early 
patients achieved a hematological response, 70% vs 25%, 
giving support to conclusions in previous studies, where 
patients with a more advanced anemia responded more 
poorly. QoL was investigated with FACT-An and LASA, 
and there was a signiﬁ  cant difference between groups with 
both instruments. The mean change in the total FACT-An 
favored early patients by 8.2 points (p = 0.003), and early 
patients had signiﬁ  cantly more improvement in all three 
LASA domain scores for daily activity (p = 0.008), energy 
(p = 0.007), and important activity (p = 0.045). Again, the 
correlation between treatment-related changes in Hb level 
and QoL effects was demonstrated (p   0.05).
This study gives support for the selection of patients for 
treatment who start to decline in Hb level early in a series 
of cytostatic treatments. It has previously been shown that 
a low-normal Hb level at the start of cytostatic treatment 
is the strongest predictive factor for later anemia (Ludwig 
et al 2004), both in cancer in general and in myeloma and 
lymphoma (Birgegård et al 2006). A recent analysis of the 
beneﬁ  t of early anemia treatment gives further support to 
this strategy (Lyman and Glaspy 2006).
Cancer patients survive longer in modern medicine, and 
palliative treatment may extend over long periods of time. 
Therefore, ESA treatment is not only indicated in patients 
given curative chemotherapy. It may be argued that uphold-
ing a good QoL through anemia correction is even more 
important in patients who have indolent or progressive 
disease and a life expectancy of more than a few months. 
Transfusion therapy usually does not aim at keeping the 
Hb level higher than about 10 g/dl, and recent studies show 
important gains in QoL when Hb is increased from this level 
to above12 g/dl.
A new concept: Improved response
with IV iron addition
There are two reasons why addition of iron could be beneﬁ  cial 
for response to ESA. First of all, some patients have small iron 
stores that will be rapidly exhausted if erythropoiesis is stimu-
lated. A plasma ferritin below 100 indicates that iron stores 
are too small to sustain a new production of red cells from a 
moderate anemia to normal Hb levels. Secondly, cancer patients 
often have FID, a condition where the turnover of iron from 
senescent red cells is disturbed: iron is locked inside macro-
phages and the transport of iron to the erythroblasts is reduced, 
causing iron starvation of the erythroblasts (see above). FID 
therefore is characterized by a normal or elevated plasma ferri-
tin, indicating presence or even elevation of iron stores, and low 
transferrin saturation. Apart from these simple measurements, 
other analyses may be used. In all situations where the erythro-
blasts need more iron more transferrin receptors (TfR) will be 
expressed on the surface of the cells, and the level of soluble 
sTfR increases. Transferrin saturation (Tsat) may be said to 
represent the functional iron compartment, whereas s-ferritin 
represents the storage compartment. A combination of serum 
ferritin and sTfR, the so called sTfR-F index, is a very reliable 
indicator of depleted iron stores (Punnonen et al 1997).
Diagnosis of functional iron deﬁ  ciency
There is a need for identiﬁ  cation of patients with FID before 
treatment, since this condition is a hinder for response to ESA. Therapeutics and Clinical Risk Management 2008:4(2) 534
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In renal anemia, this problem is well known and described, 
and it has been shown that the measurement of the percent-
age of hypochromic red cells in the blood (% HYPO) and the 
hemoglobin content of reticulocytes (CHr) are reliable indica-
tors of FID (Fishbane et al 1997; Macdougall 1998). In cancer 
anemia, a combination of % HYPO, TfR, and CHr have been 
used to create a diagnostic plot which effectively identiﬁ  es 
FID (Thomas et al 2006). Recently, this has been simpliﬁ  ed 
to include % HYPO and sTfR index and most recently % 
HYPO alone (Katodritou et al 2007). Unfortunately, the most 
commonly used automated analysis systems like Sysmex or 
Coulter can not measure % HYPO or CHr, and clinicians are 
therefore forced to rely on the less reliable sTfR alone or, in 
many cases, Tsat in combination with s-ferritin. The sensitiv-
ity and positive predictive value of Tsat alone is rather low 
(Katodritou et al 2007). As a practical and pragmatic rule 
for clinicians without access to % HYPO, CHr, or sTfR, the 
combination of normal or high ferritin and low Tsat ( 20%) 
is a strong indication of functional iron deﬁ  ciency. Lately, a 
new marker that can be analyzed with the Sysmex system, the 
RET-Y, has been investigated. The RET-Y is the mean value 
of the forward-scattered light histogram within the reticulo-
cyte population. A close correlation with CHr was found in 
474 patients (Franck et al 2004). The use of this variable in 
a cancer population has yet to be deﬁ  ned.
The importance of changes in iron turnover in cancer 
anemia was not clear when many of the ESA studies were 
planned, and often information about iron supplementation is 
missing. Generally, iron deﬁ  ciency, deﬁ  ned as a low serum 
ferritin level, has been an exclusion criterion. However, 
investigation of bone marrow iron has rarely been performed, 
and diagnosis of FID has not been made. Iron supplementa-
tion, when deﬁ  ned, has mostly been given orally.
Results of IV iron addition in cancer anemia
In renal anemia, the concept of FID and its treatment have been 
well known. The superiority of IV over oral iron supplementa-
tion has been shown, and a ESA-saving effect has been found 
in randomized, controlled studies already in the mid-90’s 
(Fishbane et al 1995; Macdougall et al 1996; Auerbach et al 
2004). In cancer anemia, the ﬁ  rst randomized study show-
ing an increased Hb response with IV iron was published in 
2004 (Auerbach et al 2004). This was a randomized study in 
157 patients receiving chemotherapy treatment and rHuEpo 
40,000 U per week and compared the addition of oral or IV iron 
dextran to no iron. A signiﬁ  cant difference in response rates 
was found, 68% for IV iron vs. 36% for oral iron and 25% for 
no iron (p   0.01). Eligible for the study were patients with 
Hb   10.5 g/dl and s-ferritin  450 pmol/L or  675 pmol/L 
and Tsat   19%. Bone marrow iron staining was not per-
formed. The study has been questioned because of the unusu-
ally low response rates in the no-iron and oral-iron groups, 
which may have been caused by the short treatment duration, 
6 weeks, and by the presence of true iron deﬁ  ciency.
In another randomized, open-label study, 187 nonmyeloid 
patients with chemotherapy-related anemia were scheduled to 
receive rHuEpo 40,000 U/week, one group receiving 125 mg 
of ferric gluconate IV once weekly, another group 325 mg 
or oral ferrous sulphate three times daily and a third group 
no iron supplementation (Henry et al 2007). The inclusion 
criteria differed from the previous study: Hb   11 g/dl, 
s-ferritin  100 ng/ml or Tsat   15%. In this way, true iron 
deﬁ  ciency was probably to a large extent avoided, although 
no bone marrow iron staining was performed. However, 
patients with FID and s-ferritin  100 ng/ml and Tsat   15% 
may have been excluded. The treatment time was short also 
in this study, 8 weeks. Of the 187 patients recruited, 154 
completed the study and only 129 were evaluable for efﬁ  -
cacy, mainly due to early transfusions or discontinuations. 
The results showed signiﬁ  cant differences between the Iv 
iron group and the other two groups in Hb increase, 2.4 g/dl, 
1.6 g/dl, and 1.5 g/dl, respectively (p = 0.0044 for IV vs. no 
iron), in response rates, 73%, 45%, and 41% respectively 
(p = 0.029 for IV vs. no iron). Interestingly, the subgroup with 
the lowest Tsat, below 20%, had a response rate of 81% in the 
IV iron group compared with 37% in the oral iron group and 
27% in the no-iron group. It may be assumed that most of the 
patients with low Tsat had FID, even though some true iron 
deﬁ  ciency patients may have been included. Patients with 
Tsat   20% had a lower response rate to IV iron than those 
with Tsat   20% (68 vs 81%). This underlines the importance 
of the iron need, indicated by a low Tsat.
The third and most recent study (Hedenus et al 2007) 
randomized 67 lymphoproliferative patients without chemo-
therapy, with Hb 9–11 g/dl and proven iron stores, shown 
by a positive bone marrow Prussian blue staining to receive 
rHuEpo 30,000 U once weekly plus or minus IV iron sucrose 
100 mg weekly during week 1–6, then every second week 
during week 8–14. The treatment time was 16 weeks. The 
study was powered to detect a mean Hb increase difference 
of 1g/dl. There was a signiﬁ  cant difference between the IV 
iron group and the no-iron group with regard to response rate 
(Hb increase  2 g/dl), 93% vs. 53% (p = 0.001) (Figure 4). 
The time to response was half as long and the Hb increase 
was greater (2.91 vs. 1.5 g/dl, p = 0.0001). The ﬁ  gures for per 
protocol- and intention-to-treat populations were similar.Therapeutics and Clinical Risk Management 2008:4(2) 535
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Since true iron deﬁ  ciency was excluded by bone marrow 
iron staining in this study, the 39% of the whole population 
with Tsat   20% may be regarded as FID, underlining the 
importance of this condition in cancer patients. All patients 
with Tsat   20% in the IV iron group responded with a Hb 
increase  2 g/dl. The difference in treatment results between 
the IV iron and no-iron groups was also due to the fact that 
some patients in the no-iron group had iron stores insufﬁ  cient 
to support a Hb increase  2g/dl, showed by the fact that one 
third of these patients reached subnormal s-ferritin levels 
during the study and that the Tsat fell below 20% in all the 
patients in this group with a normal Tsat at base-line.
A reduction in rHuEpo need was seen in the IV iron 
group. At the end of the study, a 25% difference (10000 U 
per week) in Epo dose was seen between the arms, and the 
mean total cumulative dose per patient was 511 vs. 626 
thousand U (p = 0.051). The study was not powered to prove 
this difference, but the borderline signiﬁ  cance is notable and 
supports results from the studies in renal anemia. The dif-
ference translates into a cost reduction of at least $100 per 
week, depending on local list prices of ESA.
In conclusion, the improvement in efficacy of ESA 
treatment by addition of IV iron has now been convincingly 
shown both in renal and cancer anemia. The mechanism is 
known. Some questions remain unanswered, though. How 
many patients with FID would respond to monotherapy with 
IV iron without ESA? Would oral iron treatment sufﬁ  ce for 
patients with small iron stores (s-ferritin   100 ug/L but 
within the reference range) and no sign of FID (Tsat   20, 
normal % HYPO)?
Are there risks with IV iron treatment?
So far, no negative effects of iron addition have been found. 
However, no study has been powered or long enough for 
survival analysis. There is a fear that iron overload may 
ensue, especially in maintenance treatment, and that this 
would cause the formation of toxic oxygen radicals that 
could promote tumour growth or cause organ damage. There 
is room for some caution, therefore, and in further studies, 
survival needs to be an important endpoint. A reasonable 
mode of treatment is to monitor the s-ferritin levels, making 
certain that gross iron overload is avoided by reducing iron 
doses when s-ferritin increases over a certain limit. This 
means making sure that the patient uses the iron given for 
erythropoiesis. It is a matter of debate what the s-ferritin limit 
should be, and there is no data in the literature to support the 
Figure 4 Hemoglobin response rates were signiﬁ  cantly higher in the group with additional IV iron during ESA treatment, 93% vs 53%, and the response (Hb increase  2 g/dl) 
was twice as quick in this group. Copyright © 2007. Reproduced from Hedenus M, Birgegård G, Näsman P, et al 2007. Addition of intravenous iron to epoetin beta increases 
hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 
21:627–32.
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choice. It must be remembered that s-ferritin often is elevated 
beyond the level reﬂ  ecting the iron stores in cancer patients 
due to its property as an acute phase reactant, responding to 
inﬂ  ammatory cytokines.
The EORTC guidelines were published before the last 
two studies of IV iron supplement in cancer anemia. Still, the 
guidelines state that there was grade B evidence to support 
improved response of ESA with addition of IV iron and that 
oral iron is ineffective in functional iron deﬁ  ciency.
It is obvious that both functional iron deﬁ  ciency and 
small iron stores are very important factors to consider when 
starting ESA treatment.
Evaluation of treatment effects
Randomized, placebo-controlled studies have convincingly 
shown the efﬁ  cacy and effectiveness of ESA therapy for 
cancer anemia in general and for anemia in myeloma and 
lymphoma, for patients with or without chemotherapy. The 
effectiveness is now well established on a group level, and 
an individualised approach is necessary. All patients do not 
respond, and all patients who respond with an increase in Hb 
do not experience QoL gains. Therefore, a careful monitor-
ing of individual patients is necessary with an evaluation of 
treatment effects, objectively and subjectively. In clinical 
practice, a part of the high cost of ESA treatment in total is 
probably a waste of drug in patients who are not taken off 
treatment in spite of non-responsiveness. An increase in Hb 
should be expected within 6 weeks. Unfortunately, there is 
no reliable early marker of response. Attempts have been 
made to combine markers like reticulocyte counts, transfer-
rin receptor and s-ferritin in order to identify nonresponding 
patients within the ﬁ  rst weeks of treatment (Cazzola et al 
1996; Beguin 1998; Tonelli et al 2001), but none of these has 
been consistently reliable. A recent attempt to use the increase 
in beta-globin mRNA during the ﬁ  rst two weeks of therapy 
is interesting but needs further investigation (Hagberg et al 
2003; Birgegård et al 2007). Still, Hb increase after 4–6 
weeks is the only reliable response indicator.
With regard to effectiveness in alleviating symptoms 
or improving functional capacity, the QoL instruments 
used in clinical trials, although showing good consistency 
and reliability, are generally too cumbersome to use with 
individual patients. Van Belle and colleagues (2005) have 
compared proposed diagnostic criteria with FACT-F and 
VAS for cancer-related fatigue. The internal consistency of 
the ICD-10 and the FACT-F, expressed as Crohnbach´s alpha 
coefﬁ  cient were 0.82 and 0.89, respectively, in a material 
of 834 patients. The diagnostic tool ICD-10 and FACT-F 
correlated well for individual symptoms, except for items 
assessing memory performance and emotional problems. 
It was concluded that both instruments evaluate physical 
symptoms more reliably than psychological and emotional. 
The ICD-10 was recommended as a diagnostic tool, whereas 
the FACT-F scale also assesses the intensity of fatigue and 
is suitable for follow-up studies.
In comparison to the other two, the VAS (or LASA) tool 
is easy and rapid to complete and very intuitive for patients. 
On a visual analogue scale the patient indicates a value for 
three domains: energy level, activity level and general QoL. 
The VAS scale showed good agreement with the other two 
and is rapid, easy-to-use tool for longitudinal follow-up.
Dosing and choice of ESA
Attempts have been made to increase efﬁ  cacy by using a higher 
dose of ESA during the ﬁ  rst weeks of therapy (Hesketh et al 
2004). Only one study has compared the standard ﬁ  xed dose 
versus weight-based dose. In both cases, there is not enough 
evidence to support these strategies (Ludwig et al 2004).
The earlier standard dosing of three times weekly has now 
been largely abandoned since more than ﬁ  fty studies have 
provided evidence for less frequent dosing, the most common 
being once weekly. Darbepoetin alfa, which was designed to 
have a longer half-life, has been shown to be effective with a 
Q3w dosing (Steensma et al 2006). In clinical practice, many 
have seen that patients with a good hematopoietic response 
to ESA may be maintained with Q2W or Q3W dosing of 
Epo α or β as well (personal experience). The choice of 
ESA is not a matter of efﬁ  cacy, and all ESA on the market 
are recommended in the published guidelines.
New compounds that are not Epo molecules, but are 
smaller peptides stimulating the Epo receptor are being 
investigated but are not yet on the market and are not included 
in this survey.
Possible negative effects of ESA treatment
in myeloma and lymphoma
Cancer patients in general have an increased incidence of 
thrombosis, and a further increase has been found in ESA-
treated patients. A meta-analysis with data from 9353 patients 
in 57 trials concluded that there was evidence that ESA 
signiﬁ  cantly increased the risk of thrombosis or related com-
plications (RR=1.67; CI 1.35, 2.06) (Bohlius et al 2006b). 
The recommended treatment goal of Hb 12 g/dl should be 
used in order to minimize this risk.
Pure red cell aplasia (PRCA) is a very rare complica-
tion of ESA treatment. Any protein injected into a human Therapeutics and Clinical Risk Management 2008:4(2) 537
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may cause antibody formation, and ESA are no exceptions. 
However, biologically active antibodies against erythro-
cyte precursors are rare, except during a period of a few 
years after 1998, when one of the ESA preparations due to 
a change in the manufacturing process gave rise to about 
200 cases of PRCA world-wide (Casadevall et al 2002). 
Almost all cases had renal anemia, and after 2002, when the 
manufacturing process was changed again, the incidence of 
PRCA has returned to a very low level, again making it a 
rare problem.
The ongoing discussion about possible negative effects on 
survival and tumor control in solid tumors is of less relevance 
in hematological malignancies. There is no study indicating 
any negative effect. On the contrary, there are a few stud-
ies indicating a positive effect, and a recent meta-analysis 
(Bohlius et al 2006a) as well as a long term follow-up study 
(Osterborg et al 2005) fail to show any difference between 
ESA treatment and placebo. As discussed above, the pres-
ence of EpoRs on tumor cells is not surprising, since a wide 
variety of normal tissues also express the EpoR in the same 
amounts. In lymphoproliferative disease, no in vivo or in 
vitro data indicate any tumour stimulation.
Conclusions
ESA treatment of anemia in lymphproliferative disorders 
has been shown to be both efﬁ  cacious and effective. Even if 
avoidance of red cell transfusions is an important treatment 
goal, the main reason for ESA treatment is improvement 
of QoL. Recent guidelines stress the latter goal and recom-
mend treatment also in mild and moderate anemia, related 
to symptoms. The recent ﬁ  ndings of the drug cost saving 
and the improvement of response rates with the addition 
of IV iron is an important step forward in optimizing ESA 
treatment.
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